Table 1—

Changes in major and emerging CVD risk factors during and between the Salba and control treatments (n = 20)

Salba
Control
Between treatment
Week 0Week 12Change (%)Week 0Week 12Change (%)Change (%)P value
Major CVD risk factors
    A1C (%)6.9 ± 0.86.7 ± 0.9−2.9 ± 8.4*6.7 ± 0.86.7 ± 0.9−0.2 ± 6.7−2.6 ± 12.40.37
    Fasting blood glucose (mmol/l)7.4 ± 2.17.2 ± 1.9−0.7 ± 21.77.1 ± 1.57.6 ± 1.94.1 ± 11.6−7.3 ± 25.50.12
    Fasting blood insulin (pmol/l)74.4 ± 28.886.1 ± 39.117.5 ± 34.782.2 ± 35.685.1 ± 44.43.5 ± 25.214.0 ± 43.20.24
    Total cholesterol (mmol/l)5.1 ± 1.24.9 ± 1.2−2.3 ± 1.25.0 ± 1.25.0 ± 1.20.5 ± 1.2−2.8 ± 0.60.47
    LDL cholesterol (mmol/l)3.0 ± 1.03.0 ± 1.0−1.2 ± 1.02.9 ± 0.93.0 ± 1.02.0 ± 1.0−3.2 ± 0.40.56
    HDL cholesterol (mmol/l)1.3 ± 0.21.2 ± 0.3−5.2 ± 0.31.2 ± 0.31.2 ± 0.2−1.5 ± 0.3−3.7 ± 0.10.26
    Triglycerides (mmol/l)1.6 ± 0.81.6 ± 0.8−1.7 ± 0.81.7 ± 0.91.7 ± 0.8−2.1 ± 0.80.4 ± 0.40.95
    SBP (mmHg)129 ± 17123 ± 16−9.5 ± 1*122 ± 15129 ± 1710 ± 2*−20 ± 1>0.01
    DBP (mmHg)81 ± 978 ± 8−3 ± 1.376 ± 979 ± 79.2 ± 1.3*−7 ± 1>0.05
Emerging CVD risk factors
    hs-CRP (mg/l)3.1 ± 2.42.9 ± 2.3−7.0 ± 2.32.6 ± 2.13.4 ± 2.332.9 ± 2.2*−39.9 ± 1.60.04
    Fibrinogen (g/l)3.52 ± 0.763.37 ± 0.61−5.32 ± 0.68*3.24 ± 0.693.35 ± 0.713.57 ± 0.69−8.89 ± 0.520.1
    vWF1.14 ± 0.381.038 ± 0.45−9.12 ± 0.411.158 ± 0.661.299 ± 0.6112.13 ± 0.63−21.25 ± 0.340.03
    Factor VIII1.04 ± 0.360.95 ± 0.36−8.68 ± 0.360.85 ± 0.390.97 ± 0.4714.3 ± 0.43−22.98 ± 0.290.06
  • Data are means ± SD and represent measures of efficacy. The safety and compliance data are described in the text. P values refer to between-treatment differences using repeated-measures general linear model ANOVA adjusted for age, sex, weight, antihyperglycemic agents (A1C, fasting blood glucose, and fasting blood insulin); for age, sex, weight, BMI, lipid-lowering medications (total, LDL, and HDL cholesterol; triglycerides; and hs-CRP); for age, sex, weight, and aspirin use (fibrinogen, vWF, and factor VIII); and for age, sex, weight, and blood pressure medications (SBP and DBP). Percent changes for each variable are based on the calculation for each individual subject’s percent change.

  • *

    * P < 0.05.